Sepha launches small batch contract packaging service amid rising demand
The CPO's new division will offer a holistic blister packaging development service, complete with QA and non-destructive leak testing, encompassing material selection, tooling design, and 3D prototyping
Sepha has launched a contract packaging service to serve the pharmaceutical, nutraceutical, and medical device industries in response to what it described as a recent explosion in demand for small batch production.
A number of factors account for this surge in demand, including the rise of personalized medicines and orphan drugs, as well as the industry's need to produce small batches economically.
According to Paul Smith, Managing Director of Sepha, some customers were having to halt 24/7 high-speed blister lines to produce a few hundred sample packs. "This is not what these lines were designed for and cannot be justified in terms of line clearance and changeover times," he said.
This trend has led to larger pharmaceutical manufacturers and contract manufacturing organisations (CMOs) struggling to accommodate occasional low volumes on their high-speed production lines.
Sepha, therefore, has introduced the new service in response to this challenge amid increasing calls for support from its larger pharmaceutical customers.
"We see ourselves working in partnership rather than in competition with large CMOs," said Smith.
The company's new contract packaging offer focuses on providing cost-effective, low volume runs of blister and medical device packs within short turnarounds.
Operating from a new packaging facility in Belfast, the service produces packs for sampling, testing, and research, independent of the availability of larger blister pack lines.
Housing a range of blister packaging equipment, the facility accommodates the gamut of small-batch packaging projects, from cold-form and thermoform blisters to MAP packs, trays for medical devices, and temperature and humidity-controlled packaging.
The company's design experience enables them to offer a holistic blister packaging development service, complete with QA and non-destructive leak testing. Encompassing material selection, tooling design, and 3D prototyping, the full-service offering is geared to manufacturers looking to test or compare different materials and designs on a pilot scale.
The new contract packaging service targets companies looking to outsource anything from 100 up to 10,000 packs per week, either as one-off runs or longer-term contracts. These might be packs for use in stability studies, multiple formats for patient compliance testing, or marketing samples, for example.
Multinational pharmaceutical manufacturers wanting to focus on drug development and outsource the packaging of solid dose tablets, capsules, and medical devices will be the main beneficiaries.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance